Proposition - PharmXpert Academy

More documents

Recommendations

Info

The Korean Pharmaceutical Company List 471 2. Main Products Information No. The Name of Products Main Ingredient Use (Indications) Formulation The Date of Sales Expected Exporting Countries Etc. 1 Thioctin Thioctic acid treatment of diabetic polyneuropathy tablet 2 CONIEL Tab Benidipine HCl Hypertension tablet 3 KARTER Carvedilol Essential hypertension tablet 4 PROLOLER. Tab Metoprolol succinate Hypertention tablet 5 CADRATEN Tab Cadralazine 6 GLIBOMET Tab Glibenclamide 7 MEVIL Tab 8 ALVEOTEN syr Dried aluminum hydroxide gel Neltenexine monohydrate 9 ALVEOTEN Tab Neltenexine monohydrate 10 BUROXAM Tab Ibuproxam Essential hypertension and renal hypertension Non-insulin dependent diabetes mellitus (Type Ⅱ) that cannot be controlled with diet Hyperchylia, brash Acute & Chronic bronchitis Acute & Chronic bronchitis Rheumatoid arthritis, osteoarthritis tablet tablet tablet syrub tablet tablet
472 2007 Korea Pharmaceutical Industry Directory 48. MyungMoon Pharm 1. Company Information Company MyungMoon Pharm Representative Kyu-Huok, Lee E-mail mmpharm@mmpharm.co.kr Representative Phone No. Hompage Address Research Institute Address Year of Establishment The Number of Employees (06‘) 02-7611-2000 http://www.mmpharm.co.kr Representative Fax No. 02-572-5137 MYUNGMOONB/D, 946-18, DOKOK-DONG, KANGNAM-GU, SEOUL, KOREA 901-1, SANGSIN-RI, HYANGNAM-MYUN, HWASUNG-SI, KYUNGKI-DO, KOREA 1983 Sales (‘06) 47.8 Million$ Total The Number of 319 Researcher (‘06) 3 Total Contact Person Kyung-Hee, Sin Contact Phone (02) 6711-2062 Contact E-mail skh12@mmpharm.co.kr Contact Fax (02) 572-5192 Introduction of Company We, Myungmoon pharmaceutical company, are proud of a remarkable growth achieved since it was first founded in 1983 with a great ambition for the pursuit of the public healthcare. “MYUNGMOON” stands in Korean as a “distinguished house” and embodies its entrepreneurial spirit with a motto “pioneers of the public healthcare in harmony with human resources challenging the future.” One of the highlights in the past decade was the introduction of transdermal therapeutic system which was recognized as an introduction of transdermal therapeutic system which was recognized as an introductive chapter to the Korean pharmaceutical industry thanks to our research and development effort resulted in a new galenical form called PATCH. Now, we would like to do our utmost towards the 21st century for embodiment of the entrepreneurial spirit. For the purpose of realizing our mission, we will continue to upgrade our research and development efforts to be a specialized and characterized pharmaceustical company, as well as realize the effective total marketing and business philosophy. We will exert our efforts towards improving the national health and welfare through continuous research and development of the most advanced medicines until all diseases on this land are disappeared. We hope that we can continue to enjoy your enthusiastic support and untiring guidance in the future as well.
Page 2 and 3:
2007 Korea Pharmaceutical Industry
Page 4 and 5:
2007 Korea Pharmaceutical Industry
Page 6 and 7:
27. ILYANG PHARM ·········
Page 8 and 9:
Chapter 1. Outline of The Project 2
Page 10 and 11:
Chapter 1. Outline of The Project 2
Page 12 and 13:
Chapter 2. Pharmaceutical Industry
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
The Annex
Page 38 and 39:
316 2007 Korea Pharmaceutical Indus
Page 40 and 41:
The Korean Pharmaceutical Company L
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
4. Company Map The Korean Pharmace
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143: The Korean Pharmaceutical Company L
Page 200 and 201: 4. Company Map The Korean Pharmace
Page 242 and 243:
Page 244 and 245:
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
show all

Proposition - PharmXpert Academy

Create successful ePaper yourself

Delete template?

Save as template?